Betaliq has enrolled the first patient in a phase 2 trial investigating BTQ-1901 and BTQ-1902 for the treatment of glaucoma or ocular hypertension, according to a press release.
The multicenter, double-masked, parallel-group, dose-ranging study will take place over 12 weeks and aims to enroll about 240 patients. The trial will investigate the safety and efficacy of BTQ-1901 (0.5% and 1% concentrations) and BTQ-1902 ophthalmic suspensions compared with timolol ophthalmic solution 0.5% in adults with elevated IOP due to primary open-angle glaucoma or ocular hypertension. IOP will be compared